Jasper Therapeutics Inc
For the period ended Dec 31, 2023. Filed Mar 5, 2024.
View on SEC.govAbout this filing
A company's yearly report to the SEC, with audited financial statements. It is the fullest account a company gives of its business, its finances and the risks it sees.
FY2023 · Filed Mar 5, 2024
JSPR$14.75-9.9%Stored close · as of Nov 10, 2026
Extracted filing text, with the paragraph anchors used by the comparison.
See the whole filing, with its images and exhibitsContents
Consolidated Statements of Stockholders’ Equity
(in thousands, except share data)
| Common Stock · Additional Paid-In · Accumulated · Total Stockholders’ | |||||
|---|---|---|---|---|---|
| Shares | Amount | Capital | Deficit | Equity | |
| Balance as of December 31, 2021 | 3,785,383 | $— | $136,968 | $(67,450) | $69,518 |
| Issuance of common stock upon exercise of stock options | 3,727 | — | 27 | — | 27 |
| Issuance of common stock upon exercise of common stock warrants | 2 | — | — | — | — |
| Issuance of common stock pursuant to Employee Stock Purchase Plan | 5,942 | — | 28 | — | 28 |
| Settlement of restricted stock units | 9,373 | — | — | — | — |
| Vesting of founders’ restricted stock | — | — | 10 | — | 10 |
| Stock-based compensation expense | — | — | 4,091 | — | 4,091 |
| Net loss | — | — | — | (37,685) | (37,685) |
| Balance as of December 31, 2022 | 3,804,427 | — | 141,124 | (105,135) | 35,989 |
| Issuance of common stock upon exercise of stock options | 54,580 | — | 388 | — | 388 |
| Issuance of common stock through underwritten offering, net of discounts and commissions and offering expenses of $6.6 million | 6,900,000 | 1 | 96,969 | — | 96,970 |
| Issuance of common stock through ATM offering, net of commissions and offering expenses of $0.1 million | 233,747 | — | 4,509 | — | 4,509 |
| Reclassification of common stock warrants from liability to equity (Note 7) | — | — | 725 | — | 725 |
| Settlement of restricted stock units | 238,605 | — | — | — | — |
| Shares withheld for taxes | (80,462) | — | (960) | — | (960) |
| Issuance of common stock pursuant to Employee Stock Purchase Plan | 12,999 | — | 64 | — | 64 |
| Vesting of founders’ restricted stock | — | — | 9 | — | 9 |
| Stock-based compensation expense | — | — | 5,211 | — | 5,211 |
| Net loss | — | — | — | (64,465) | (64,465) |
| Balance as of December 31, 2023 | 11,163,896 | $1 | $248,039 | $(169,600) | $78,440 |
The text of this filing, as the company filed it with the SEC, without its images or exhibits. This is not investment advice.